NARLUMOSBART
UNII J38KT46AH8

Substance Identification & Data

This profile provides standardized clinical and technical data for Narlumosbart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) J38KT46AH8.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2646587-68-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

J38KT46AH8

CAS Registry Number

2646587-68-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

NARLUMOSBART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C190458

National Cancer Institute reference terminology for clinical and research data.

INN ID

12344

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Narlumosbart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

NARLUMOSBART

Common Names & Synonyms

GAMMA4 HEAVY CHAIN HOMO SAPIENS (1-449) (VH(HOMO SAPIENS IGHV3-23*01 (98.0%)-(IGHD)-IGHJ5*02 (93.8%), CDR-IMGT (8.8.15) (26-33.51-58.97-111)) (1-122)-HOMO SAPIENS IGHG4*01, G4V5 HP10, NG4M(A) CH2 L92 (CH1(123-220), HINGE 1-12, S10>P(230) (221-232), CH2 L92 (311) (233-342), CH3 (343-447), CHS (448-449)) (123-449)), (136-215')-DISULFIDE WITH KAPPA LIGHT CHAIN HOMO SAPIENS (1'-215') (V-KAPPA (HOMO SAPIENS IGKV3-20*01 (85.8%)-IGKJ1*01 (100%), CDR-IMGT (7.3.9) (27-33.51-53.90-98)) (1'-108') -HOMO SAPIENS IGKC*01(100%), KM3 A45.1 (154), V101 (192) (109'-215')), DIMER (228-228'':231-231'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-S, GLYCOFORM ALFA

IMMUNOGLOBULIN G4 (230-PROLINE), ANTI-(HUMAN OSTEOCLAST DIFFERENTIATION FACTOR) (HUMAN MONOCLONAL JMT103 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL JMT103 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G4-KAPPA, ANTI-(TNFSF11 (TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY MEMBER 11, OSTEOCLAST DIFFERENTIATION FACTOR, ODF, OPGL, RANKL, TRANCE, CD254)), HOMO SAPIENS MONOCLONAL ANTIBODY

NARLUMOSBART [INN]

NARLUMOSBART [WHO-DD]

External Clinical & Regulatory Resources

Previous UNIIJ38K126SZE

Next UNIIJ38U4758MY